GlassScriptPhysician profile
Israel S Eckman
NPI 1184671612
$2,565.77
in general payments reported to CMS, 2019-2025
22 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2022: $416 · 2023: $377 · 2024: $219 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.07 |
| Education | $383.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $323.42 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $287.33 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $249.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $199.98 | 2022-2023 | |
| Amgen INC. | $196.97 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $175.08 | 2022-2025 | Opzelura |
| Abbvie INC. | $151.84 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $138.55 | 2023-2025 | Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $137.25 | 2024-2025 | Zoryve |
| Dermira, INC. | $136.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $128.27 | 2025 | Dupixent |
| Organon LLC | $90.56 | 2025 | Vtama |
| Pfizer INC. | $75.63 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $74.64 | 2025 | Sotyktu |
| Journey Medical Corporation | $47.76 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.29 | 2025 | |
| Mayne Pharma Commercial LLC | $24.57 | 2024 | |
| Strata Skin Sciences, INC. | $23.76 | 2025 | Xtrac |
| Galderma Laboratories, L.P. | $23.02 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.42 | 2025 | Cabtreo |
| Dermavant Sciences, INC. | $15.82 | 2024 | Vtama |
| Leo Pharma INC. | $13.94 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Israel Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.